Living with plaque psoriasis can mean dealing with persistent, itchy, and uncomfortable skin patches. A recent trial looked at how the medication guselkumab helps patients manage this condition. The study focused on 327 Chinese patients with moderate to severe cases of the disease.
Researchers found that patients who received guselkumab saw much better results early on. By week 16, over 82% of those on the medication reached a high level of skin clearance, compared to only 2% in the group that started with a placebo. The study also showed a favorable safety profile, with very few serious side effects reported during the first 16 weeks.
While the results were very strong at the 16-week mark, the study notes that data from randomized trials specifically in the Chinese population is still limited. However, the findings suggest that guselkumab is a highly effective option for those seeking to clear their skin and manage their symptoms.
Common questions
How effective is guselkumab for plaque psoriasis?
The trial showed that guselkumab was highly effective. By week 16, 82.4% of patients taking the medication achieved a high level of skin clearance (PASI 90), compared to only 2% in the placebo group. These results were consistent with a favorable safety profile for patients with moderate to severe cases.
Is guselkumab safe for patients with psoriasis?
The study reported a favorable safety profile for guselkumab. During the first 16 weeks, only 0.9% of patients in the guselkumab group experienced serious adverse events, which was lower than the 5.5% reported in the placebo group. You should discuss these results with your doctor to see if it is right for you.
How long did the study follow the patients?
The study followed patients for a total of 48 weeks. While the most significant difference between the guselkumab and placebo groups was seen at week 16, the results remained comparable between the two groups at the 48-week mark. This provides a longer look at how the treatment performs over time.
